SYnAbs and Volition ink strategic deal on epigenetic modifications targeting
24.09.2020
SYnAbs S.A.
SYnAbs and Volition ink strategic deal on epigenetic modifications targeting
SYnabs will develop monoclonal antibodies of mice, rats, and guinea pigs against 16 different post-translational modifications on histones including methylation, acetylation, phosphorylation, and mutations.